Via360 Expands Canal-Based MIGS Options - Takeaway - MDSpire
Clinical Guidelines

Via360 Expands Canal-Based MIGS Options

Share

  • 1

    Via360 integrates canaloplasty and trabeculotomy.

  • 2

    It features ActiveInject technology for surgeon-controlled viscodilation.

  • 3

    FDA cleared in February

  • 4

    Effective for various glaucoma conditions.

  • 5

    Allows for intraoperative titration of treatment.

  • 6

    Reduces reliance on topical glaucoma medications.

  • 7

    Designed for high-volume surgical settings.

  • 8

    Compatible with adjunctive therapies, maximizing treatment options.

Original Source(s)

Via360 Expands Canal-Based MIGS Options

  • by Jim Gallagher, senior managing editor

  • May 1, 2026

Related Content

GA Gene Therapy Interest Increases

Phase I trial results of PulseSight Therapeutics’ PST-611 to be presented at ARVO 2026

  • May 1, 2026

  • 2 min
Ocugen GA Trial Advances Toward Phase 3

Ocugen reports positive Phase 2 data for its OCU410 gene therapy in geographic atrophy

  • May 1, 2026

  • 3 min
TULIP: A New Approach to IOP Reduction

Low-power ultrasound biomodulation may offer a noninvasive, repeatable strategy to lower IOP without tissue destruction.